Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma:A literature review  

作　　者：Lakshan N Fonseka Benjamin KP Woo 

机构地区：[1]Harvard South Shore-Psychiatry Residency Program,Veteran Affairs Boston Healthcare System,Brockton,MA 02301,United States [2]Chinese American Health Promotion Laboratory,University of California,Los Angeles,Los Angeles,CA 90095,United States [3]Department of Psychiatry and Biobehavioral Sciences,Olive View-University of California,Los Angeles Medical Center,Sylmar,CA 91342,United States [4]Asian American Studies Center,University of California,Los Angeles,Los Angeles,CA 90095,United States [5]Podiatric Medicine and Surgery,Western University of Health Sciences,Pomona,CA 91766,United States

出　　处：《World Journal of Psychiatry》2023年第5期182-190,共9页世界精神病学杂志

摘　　要：With the Food and Drug Administration designation in 2017 of 3,4-methylenedioxymethamphetamine(MDMA)as a breakthrough therapy in post-traumatic stress disorder and psilocybin in treatment-resistant depression,psychedelic drugs have continued to garner the attention of researchers and clinicians for their promise of unmatched,rapid improvement in a multitude of psychiatric conditions.Classic psychedelic drugs including psilocybin,lysergic acid diethylamide,and ayahuasca,as well as non-classic drugs such as MDMA and ketamine,are currently being investigated for a potential therapeutic role in trauma,depressive disorders,and other psychopathologies.However,psilocybin and MDMA each have a functional profile well-suited for integration with psychotherapy.The present review focuses on psilocybin and MDMA in psychedelic-assisted therapy(PAT),as these studies compose most of the literature pool.In this review,we discuss the current and future uses of psychedelic drugs,with an emphasis on the role of MDMA and psilocybin in PAT in the setting of trauma and related comorbidities on the efficacy of psychedelic drugs across multiple psychiatric disorders.The article concludes with thoughts for future research,such as incorporating wearables and standardization of symptom scales,therapy styles,and assessment of adverse drug reactions.

关 键 词：DRUGS TRAUMA MDMA 

分 类 号：R749.5[医药卫生—神经病学与精神病学]